Q-omics provides the consensus-scored ETNK1 profile across patient tissues and cancer cell-line models. ETNK1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, ETNK1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, ETNK1 RNA expression shows 20,334 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, BLCA, and UVM as cancer lineages where ETNK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ETNK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ETNK1 survival associations across molecular data types. ETNK1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ETNK1 RNA expression–survival associations across cancer types. High ETNK1 expression shows unfavorable associations in LGG, LIHC, UVM, DLBC and KIRC, but favorable associations in HNSC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for ETNK1 RNA expression.
This table summarizes ETNK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ETNK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ETNK1 shows lower tumor expression in KIRC and THCA and higher tumor expression in BLCA, HNSC, BRCA and CHOL. The BLCA box plot shows higher ETNK1 RNA expression in tumor versus normal tissue (log2 FC = +1.142, t-test p < 0.001).
This table shows molecular features associated with ETNK1 in patient tissues and cancer cell lines. In patient samples, ETNK1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ETNK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
